Opus Genetics terminates $50M equity purchase agreement with Lincoln Park Capital

Opus Genetics, Inc.

Terminated Purchase Agreement with Lincoln Park Capital effective April 3, 2025.
Agreement allowed up to $50M in stock sales; company cites limited value given current market price.
Prior to termination, issued 1.7M shares for net proceeds of ~$5.2M; remaining $44.8M facility cancelled.
Registration obligations under the agreement survive termination for 90 days.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.